FR22C1044I1 - Antagonistes du recepteur cgrp - Google Patents

Antagonistes du recepteur cgrp

Info

Publication number: FR22C1044I1
Authority: FR; France
Prior art keywords: receptor antagonists; cgrp receptor; cgrp; antagonists; receptor
Prior art date: 2009-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1044C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-14

Filing date

2022-08-11

Publication date

2022-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1044(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-08-11 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2022-09-30 Publication of FR22C1044I1 publication Critical patent/FR22C1044I1/fr

2023-11-17 Application granted granted Critical

2023-11-17 Publication of FR22C1044I2 publication Critical patent/FR22C1044I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

FR22C1044C 2009-10-14 2022-08-11 Antagonistes du recepteur cgrp Active FR22C1044I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25147709P	2009-10-14	2009-10-14
PCT/US2010/052433 WO2011046997A1 (fr)	2009-10-14	2010-10-13	Antagonistes de récepteur cgrp

Publications (2)

Publication Number	Publication Date
FR22C1044I1 true FR22C1044I1 (fr)	2022-09-30
FR22C1044I2 FR22C1044I2 (fr)	2023-11-17

Family

ID=43242489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1044C Active FR22C1044I2 (fr)	2009-10-14	2022-08-11	Antagonistes du recepteur cgrp

Country Status (35)

Country	Link
US (2)	US8314117B2 (fr)
EP (1)	EP2488512B1 (fr)
JP (3)	JP5836279B2 (fr)
KR (3)	KR101990755B1 (fr)
CN (1)	CN102656159B (fr)
AR (2)	AR078638A1 (fr)
AU (1)	AU2010306954B2 (fr)
BR (1)	BR112012008828B1 (fr)
CA (2)	CA2777518C (fr)
CL (1)	CL2012000925A1 (fr)
CO (1)	CO6460732A2 (fr)
CY (1)	CY2022023I1 (fr)
DK (1)	DK2488512T3 (fr)
EA (1)	EA020409B1 (fr)
ES (1)	ES2441192T3 (fr)
FR (1)	FR22C1044I2 (fr)
HR (1)	HRP20140111T1 (fr)
HU (1)	HUS2200033I1 (fr)
IL (1)	IL219120A (fr)
LT (1)	LTC2488512I2 (fr)
LU (1)	LUC00272I2 (fr)
MX (1)	MX2012004182A (fr)
NL (1)	NL301187I2 (fr)
NO (1)	NO2022033I1 (fr)
NZ (1)	NZ599281A (fr)
PE (1)	PE20121137A1 (fr)
PL (1)	PL2488512T3 (fr)
PT (1)	PT2488512E (fr)
RS (1)	RS53149B (fr)
SI (1)	SI2488512T1 (fr)
SM (1)	SMT201400019B (fr)
TN (1)	TN2012000139A1 (fr)
TW (1)	TWI465448B (fr)
WO (1)	WO2011046997A1 (fr)
ZA (1)	ZA201203452B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8669368B2 (en) *	2010-10-12	2014-03-11	Bristol-Myers Squibb Company	Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) *	2011-04-12	2014-06-10	Bristol-Myers Squibb Company	CGRP receptor antagonists
KR102076118B1 (ko) *	2012-02-27	2020-02-11	브리스톨-마이어스 스큅 컴퍼니	N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염
WO2013169563A1 (fr) *	2012-05-09	2013-11-14	Merck Sharp & Dohme Corp.	Antagonistes de récepteur de cgrp à base de pyridine
EP2815749A1 (fr)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
TW201718574A (zh) *	2015-08-12	2017-06-01	美國禮來大藥廠	Ｃｇｒｐ受體拮抗劑
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
JP2021519288A (ja)	2018-03-25	2021-08-10	バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎＰｈａｒｍａｃｅｕｔｉｃａｌＨｏｌｄｉｎｇＣｏｍｐａｎｙＬｔｄ．	Ｃｇｒｐ関連障害のためのリメゲパント
CN114805206B (zh) *	2021-01-27	2025-01-14	奥锐特药业(天津)有限公司	高光学纯度瑞美吉泮中间体的工业化制备方法
KR20230157986A (ko)	2021-03-02	2023-11-17	체게에르페 다이어그노스틱스 게엠베하	편투통 발생의 치료 및/또는 저감
WO2023026205A1 (fr)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Traitement préventif de la migraine
CN115850266A (zh) *	2021-09-26	2023-03-28	奥锐特药业(天津)有限公司	瑞美吉泮新晶型及其制备方法
CN116554164B (zh) *	2022-01-27	2025-10-03	奥锐特药业(天津)有限公司	一种瑞美吉泮的制备方法
WO2023175632A1 (fr) *	2022-03-17	2023-09-21	Msn Laboratories Private Limited, R&D Center	Formes à l'état solide de (5s,6s,9r)-5-amino-6-(2,3-difluorophényl)-6,7,8,9-tétrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-pipéridinecarboxylate hémisulfate et leurs procédés de préparation
CN116478211B (zh) *	2022-04-19	2023-10-24	石家庄迪斯凯威医药科技有限公司	一种新型cgrp受体拮抗剂及其用途
CN115060824B (zh) *	2022-06-14	2024-03-12	浙江宏元药业股份有限公司	一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法
WO2024022434A1 (fr) *	2022-07-29	2024-02-01	熙源安健医药（上海）有限公司	Dérivé de pyridocycloheptane, son procédé de préparation et son utilisation
CN115677694A (zh) *	2022-11-30	2023-02-03	南通常佑药业科技有限公司	一种瑞美吉泮的合成方法
WO2024180562A1 (fr) *	2023-03-02	2024-09-06	Natco Pharma Limited	Procédé de préparation de rimégépant cristallin pur et de ses sels
CN116768938B (zh) *	2023-05-17	2025-11-11	南京艾德凯腾生物医药有限责任公司	一种铁催化剂及瑞美吉泮中间体的制备方法
WO2025061177A1 (fr) *	2023-09-21	2025-03-27	成都康弘药业集团股份有限公司	Médicament à petites molécules pour traiter un trouble lié au cgrp
CN117486798B (zh) *	2023-12-21	2025-02-07	南京威凯尔生物医药科技有限公司	一种瑞美吉泮中间体盐酸盐的晶型及其制备方法
WO2025193980A2 (fr) *	2024-03-13	2025-09-18	CNS Biosciences, Inc.	Méthode de traitement de la douleur neuropathique utilisant un inhibiteur anti-cgrp
CN119707808B (zh) *	2024-12-23	2025-12-05	上海彩迩文生化科技有限公司	一种制备cgrp受体拮抗剂中间体的方法
CN119977885A (zh) *	2025-04-15	2025-05-13	常州制药厂有限公司	(5S,6S,9R)-5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5H-环庚[b]吡啶-9-醇L-酒石酸盐及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO2355B1 (en) *	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
US7855294B2 (en)	2004-03-05	2010-12-21	Banyu Pharmaceutical Co., Ltd.	Cycloalkanopyridine derivative
RU2007117741A (ru)	2004-10-13	2008-11-20	Мерк энд Ко., Инк. (US)	Антагонисты рецептора cgrp
US20060084708A1 (en)	2004-10-14	2006-04-20	Bayer Materialscience Llc	Rigid foams with good insulation properties and a process for the production of such foams
ATE503755T1 (de)	2004-10-22	2011-04-15	Merck Sharp & Dohme	Cgrp-rezeptorantagonisten
CN101421267B (zh)	2006-04-10	2011-10-19	默沙东公司	制备吡啶杂环cgrp拮抗剂中间体的方法
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8143403B2 (en)	2008-04-11	2012-03-27	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists

2010
- 2010-10-12 US US12/902,714 patent/US8314117B2/en active Active
- 2010-10-13 PT PT107683476T patent/PT2488512E/pt unknown
- 2010-10-13 EP EP10768347.6A patent/EP2488512B1/fr active Active
- 2010-10-13 AU AU2010306954A patent/AU2010306954B2/en active Active
- 2010-10-13 HR HRP20140111AT patent/HRP20140111T1/hr unknown
- 2010-10-13 RS RS20140035A patent/RS53149B/sr unknown
- 2010-10-13 KR KR1020187018446A patent/KR101990755B1/ko active Active
- 2010-10-13 EA EA201270561A patent/EA020409B1/ru not_active IP Right Cessation
- 2010-10-13 DK DK10768347.6T patent/DK2488512T3/en active
- 2010-10-13 WO PCT/US2010/052433 patent/WO2011046997A1/fr not_active Ceased
- 2010-10-13 BR BR112012008828-9A patent/BR112012008828B1/pt active IP Right Grant
- 2010-10-13 CN CN201080056672.4A patent/CN102656159B/zh active Active
- 2010-10-13 CA CA2777518A patent/CA2777518C/fr active Active
- 2010-10-13 SI SI201030486T patent/SI2488512T1/sl unknown
- 2010-10-13 JP JP2012534309A patent/JP5836279B2/ja active Active
- 2010-10-13 KR KR1020127012197A patent/KR101755742B1/ko active Active
- 2010-10-13 MX MX2012004182A patent/MX2012004182A/es active IP Right Grant
- 2010-10-13 PE PE2012000490A patent/PE20121137A1/es active IP Right Grant
- 2010-10-13 PL PL10768347T patent/PL2488512T3/pl unknown
- 2010-10-13 NZ NZ599281A patent/NZ599281A/xx unknown
- 2010-10-13 ES ES10768347.6T patent/ES2441192T3/es active Active
- 2010-10-13 CA CA2968176A patent/CA2968176C/fr active Active
- 2010-10-13 KR KR1020177018206A patent/KR101875353B1/ko active Active
- 2010-10-14 TW TW099135091A patent/TWI465448B/zh active
- 2010-10-14 AR ARP100103755A patent/AR078638A1/es not_active Application Discontinuation
2012
- 2012-03-28 TN TNP2012000139A patent/TN2012000139A1/en unknown
- 2012-04-05 IL IL219120A patent/IL219120A/en active IP Right Grant
- 2012-04-12 CL CL2012000925A patent/CL2012000925A1/es unknown
- 2012-04-26 CO CO12068979A patent/CO6460732A2/es unknown
- 2012-05-11 ZA ZA2012/03452A patent/ZA201203452B/en unknown
- 2012-10-16 US US13/652,690 patent/US20130053570A1/en not_active Abandoned
2014
- 2014-02-17 SM SM201400019T patent/SMT201400019B/xx unknown
2015
- 2015-04-30 JP JP2015092727A patent/JP6109874B2/ja active Active
2017
- 2017-03-08 JP JP2017043761A patent/JP6258537B2/ja active Active
- 2017-11-13 AR ARP170103159A patent/AR110069A2/es not_active Application Discontinuation
2022
- 2022-07-12 CY CY2022023C patent/CY2022023I1/el unknown
- 2022-07-14 NL NL301187C patent/NL301187I2/nl unknown
- 2022-07-18 HU HUS2200033C patent/HUS2200033I1/hu unknown
- 2022-07-19 LU LU00272C patent/LUC00272I2/fr unknown
- 2022-07-22 NO NO2022033C patent/NO2022033I1/no unknown
- 2022-08-02 LT LTPA2022516C patent/LTC2488512I2/lt unknown
- 2022-08-11 FR FR22C1044C patent/FR22C1044I2/fr active Active

Also Published As

Publication number	Publication date
EP2488512A1 (fr)	2012-08-22
KR101875353B1 (ko)	2018-07-05
HK1169390A1 (en)	2013-01-25
JP2015163625A (ja)	2015-09-10
CA2968176A1 (fr)	2011-04-21
PE20121137A1 (es)	2012-08-30
MX2012004182A (es)	2012-05-29
BR112012008828A2 (pt)	2020-09-15
AR078638A1 (es)	2011-11-23
CY2022023I2 (el)	2023-01-05
CA2777518A1 (fr)	2011-04-21
LTC2488512I2 (fr)	2025-03-10
EA201270561A1 (ru)	2012-12-28
HRP20140111T1 (hr)	2014-03-14
KR20170081737A (ko)	2017-07-12
LTPA2022516I1 (fr)	2022-08-25
AU2010306954A1 (en)	2012-05-03
NL301187I2 (nl)	2022-08-04
JP2017125054A (ja)	2017-07-20
SMT201400019B (it)	2014-05-07
RS53149B (sr)	2014-06-30
TW201118096A (en)	2011-06-01
EA020409B1 (ru)	2014-10-30
TN2012000139A1 (en)	2013-09-19
AR110069A2 (es)	2019-02-20
NO2022033I1 (no)	2022-07-22
EP2488512B1 (fr)	2013-11-27
CO6460732A2 (es)	2012-06-15
AU2010306954B2 (en)	2016-05-26
IL219120A (en)	2016-12-29
US20130053570A1 (en)	2013-02-28
CA2968176C (fr)	2019-11-26
KR20120087940A (ko)	2012-08-07
IL219120A0 (en)	2012-06-28
ZA201203452B (en)	2014-10-29
KR20180080343A (ko)	2018-07-11
CL2012000925A1 (es)	2012-08-31
JP2013508281A (ja)	2013-03-07
ES2441192T3 (es)	2014-02-03
PT2488512E (pt)	2014-02-24
CN102656159A (zh)	2012-09-05
CA2777518C (fr)	2017-07-04
DK2488512T3 (en)	2014-02-24
NZ599281A (en)	2013-01-25
FR22C1044I2 (fr)	2023-11-17
LUC00272I2 (fr)	2025-05-12
TWI465448B (zh)	2014-12-21
CY2022023I1 (el)	2023-01-05
JP5836279B2 (ja)	2015-12-24
JP6258537B2 (ja)	2018-01-10
PL2488512T3 (pl)	2014-04-30
WO2011046997A1 (fr)	2011-04-21
HUS2200033I1 (hu)	2022-08-28
KR101990755B1 (ko)	2019-06-18
SI2488512T1 (sl)	2014-02-28
US8314117B2 (en)	2012-11-20
KR101755742B1 (ko)	2017-07-07
JP6109874B2 (ja)	2017-04-05
US20110251223A1 (en)	2011-10-13
CN102656159B (zh)	2015-07-01
BR112012008828B1 (pt)	2021-11-23

Publication	Publication Date	Title
FR22C1044I1 (fr)	2022-09-30	Antagonistes du recepteur cgrp
CY2023022I1 (el)	2024-02-16	Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
SMT201600078B (it)	2016-04-29	Antagonista del recettore per cgrp
PL2513093T3 (pl)	2015-03-31	Nowi antagoniści receptora CCR2 i ich zastosowanie
EP2150115A4 (fr)	2011-08-03	Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
DK2252581T3 (da)	2012-07-16	Kappa-selektiv opioidreceptorantagonist
EP2637656A4 (fr)	2014-04-23	Pipéridinone carboxamide indanes, antagonistes du récepteur cgrp
DK2443104T3 (da)	2013-05-06	Disubstituerede phthalazin-hedgehog-sti-antagonister
DK2501703T3 (da)	2013-10-14	Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0910118A2 (pt)	2015-12-29	antagonistas de receptores do glucagon
EP2654423A4 (fr)	2014-05-28	Antagonistes azaindane carboxamides hétérocycliques fusionnés de récepteurs du cgrp
EP2685826A4 (fr)	2014-09-03	Pipéridinone carboxamide spirohydantoïne, antagonistes du récepteur cgrp
DK3312169T3 (da)	2021-12-13	5-ht3 receptorantagonister
EP2254413A4 (fr)	2011-10-26	Antagonistes de récepteurs de cgrp de type imidazobenzazépine
EP2654421A4 (fr)	2014-06-18	Antagonistes des récepteurs du cgrp indanecarboxamides hétérocycliques condensés
BR112012003976A2 (pt)	2016-03-29	antagonistas de receptor glyt1 carbocíclico
EP2425008A4 (fr)	2012-11-07	Antagonistes du récepteur 3 de type toll
EP2271346A4 (fr)	2012-02-22	Antagonistes des récepteurs cgrp monocycliques
EP2458991A4 (fr)	2012-12-12	Antagonistes radio-marqués du cgrp
EP2341919A4 (fr)	2012-05-30	Antagonistes des récepteurs du cgrp
EP2340025A4 (fr)	2012-05-09	Antagonistes des récepteurs cgrp
EP2539706A4 (fr)	2013-07-31	Antagonistes arylpipérazone de récepteurs des opioïdes
BR112012005119A2 (pt)	2016-11-22	novos antagonistas de hepcidina etanodiaminas
EP2408304A4 (fr)	2012-12-12	Antagonistes de récepteurs de cgrp
EP2846800A4 (fr)	2015-11-11	Antagonistes de récepteur de cgrp hétérocycliques